SeaStar Medical’s Selective Cytopheretic Device Tech Gains Canadian Patent Protection

SeaStar Medical Holding Corporation has been issued a Canadian patent covering its Selective Cytopheretic Device (SCD) technology. 

Canadian Patent No. 2814586 expands SeaStar Medical’s international patent rights and complements its existing U.S. patent rights. “A significant opportunity exists to improve treatment of dysregulated hyperinflammatory response that can cause multiorgan damage and even death. The SCD is an innovative and proven approach that selectively targets highly active inflammatory cells to quell the hyperinflammatory response resulting from a range of conditions, and potentially reverse organ injury,” SeaStar Medical CEO Eric Schlorff said.
 
This new Canadian patent, “Cytopheretic Cartridge and Use Thereof,” provides coverage of SCD cartridges for treating activated leukocytes and activated platelets, as well as their use in processing activated leukocytes and platelets.
 
The company’s SCD is a cell-directed therapy that uses the body’s immune system to heal and can be easily added to other extracorporeal therapies such as dialysis or continuous kidney replacement therapy (CKRT). This technology targets and neutralizes activated toxic neutrophils, providing a new therapeutic approach to systemic inflammatory response syndrome. By restoring reparative physiology, the SCD can potentially reduce mortality. It has been used with other treatments including IL-6 blockers, corticosteroids and other common treatments, with few known contraindications.
 
SeaStar Medical is exploring ways for extracorporeal therapies to possibly reduce the consequences of excessive inflammation on vital organs. Its technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.